search
Back to results

CLEARI (Clinical Efficacy Assessment on Recurrent Upper-Respiratory Tract Infections) Study

Primary Purpose

Recurrent Upper-Respiratory Tract Infections

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
J022X ST
Placebo
Sponsored by
Pierre Fabre Medicament
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Recurrent Upper-Respiratory Tract Infections focused on measuring Recurrent common cold, laryngitis, pharyngitis/tonsillitis, acute rhinitis, acute rhinosinusitis, acute otitis media

Eligibility Criteria

3 Years - 4 Years (Child)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

Patients with all the following criteria will be eligible for inclusion in Year 1:

  • Children, male or female
  • Aged 3 to 4 years
  • Children known for recurrent URTIs in the past year (based on medical recording or reported history)
  • Children at risk for URTI in the physician's opinion (e.g. absence of breastfeeding, hospitalization in the previous year, tonsillectomy or adenoidectomy, parental smoking, daycare institution or nursery school, early schooling, prematurity, low weight at birth, malnutrition, failure to thrive).

Patients with all the following criteria will be eligible for randomisation in Year 2:

  • Children, male or female
  • Aged 4 to 5 years
  • Suffering from RURTI, i.e. at least 6 URTI episodes medically confirmed, with a maximum of 18, during the Year 1 of the study.

Key Exclusion Criteria:

Presence of diseases (Chronic suppurative otitis media, acute broncho-pulmonary infection, Immune deficiency or disorders, surgery of respiratory tract, cystic fibrosis…) or treatments (chronic use of corticosteroids, bronchodilators, ...) that may impact the safety, the interpretation of the results and/or the participation of the subject in the study

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

J022X ST

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Number of Upper-Respiratory Tract Infections (URTI) episodes medically assessed over year 2
Each URTI episodes will be medically assessed by the investigator by a thorough medical examination.

Secondary Outcome Measures

Full Information

First Posted
September 19, 2013
Last Updated
February 2, 2017
Sponsor
Pierre Fabre Medicament
search

1. Study Identification

Unique Protocol Identification Number
NCT01948856
Brief Title
CLEARI (Clinical Efficacy Assessment on Recurrent Upper-Respiratory Tract Infections) Study
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
September 2013 (undefined)
Primary Completion Date
October 17, 2016 (Actual)
Study Completion Date
December 13, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pierre Fabre Medicament

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to assess the efficacy and safety of J022X ST for prevention of Recurrent Upper-Respiratory Tract Infections (RURTI) compared to placebo in children of younger age who develop infectious diseases more frequently than other children of this age in general.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Recurrent Upper-Respiratory Tract Infections
Keywords
Recurrent common cold, laryngitis, pharyngitis/tonsillitis, acute rhinitis, acute rhinosinusitis, acute otitis media

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1003 (Actual)

8. Arms, Groups, and Interventions

Arm Title
J022X ST
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
J022X ST
Intervention Description
Oral administration - During 6 months and according to the approved summary of product characteristics : 1 sachet per day in the morning on an empty stomach First month: 4 consecutive days per week during 3 consecutive weeks 5 next months: 4 consecutive days per month at monthly intervals
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Oral administration - During 6 months : 1 sachet per day in the morning on an empty stomach First month: 4 consecutive days per week during 3 consecutive weeks 5 next months: 4 consecutive days per month at monthly intervals
Primary Outcome Measure Information:
Title
Number of Upper-Respiratory Tract Infections (URTI) episodes medically assessed over year 2
Description
Each URTI episodes will be medically assessed by the investigator by a thorough medical examination.
Time Frame
at each infectious episode over year 2

10. Eligibility

Sex
All
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
4 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: Patients with all the following criteria will be eligible for inclusion in Year 1: Children, male or female Aged 3 to 4 years Children known for recurrent URTIs in the past year (based on medical recording or reported history) Children at risk for URTI in the physician's opinion (e.g. absence of breastfeeding, hospitalization in the previous year, tonsillectomy or adenoidectomy, parental smoking, daycare institution or nursery school, early schooling, prematurity, low weight at birth, malnutrition, failure to thrive). Patients with all the following criteria will be eligible for randomisation in Year 2: Children, male or female Aged 4 to 5 years Suffering from RURTI, i.e. at least 6 URTI episodes medically confirmed, with a maximum of 18, during the Year 1 of the study. Key Exclusion Criteria: Presence of diseases (Chronic suppurative otitis media, acute broncho-pulmonary infection, Immune deficiency or disorders, surgery of respiratory tract, cystic fibrosis…) or treatments (chronic use of corticosteroids, bronchodilators, ...) that may impact the safety, the interpretation of the results and/or the participation of the subject in the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Karim KEDDAD, MD
Organizational Affiliation
Pierre Fabre Medicament
Official's Role
Study Director
Facility Information:
City
Ancona
Country
Italy
City
L'aquila
Country
Italy
City
Milano
Country
Italy
City
Modena
Country
Italy
City
Napoli
Country
Italy
City
Roma
Country
Italy
City
Varese
Country
Italy
City
Kaunas
Country
Lithuania
City
Panevezys
Country
Lithuania
City
Vilnius
Country
Lithuania
City
Lesznowola
Country
Poland
City
Lublin
Country
Poland
City
Ostroleka
Country
Poland
City
Warszawa
Country
Poland
City
Wegrow
Country
Poland
City
Wolomin
Country
Poland
City
Bacau
Country
Romania
City
Brasov
Country
Romania
City
Bucharest
Country
Romania
City
Constanta
Country
Romania
City
Craiova
Country
Romania
City
Sibiu
Country
Romania
City
Moscow
Country
Russian Federation
City
St.Petersburg
Country
Russian Federation

12. IPD Sharing Statement

Learn more about this trial

CLEARI (Clinical Efficacy Assessment on Recurrent Upper-Respiratory Tract Infections) Study

We'll reach out to this number within 24 hrs